Progress in systemic therapy for triple-negative breast cancer

Outline

Abstract
Keywords

Frontiers of Medicine

2021, Volume 15, Issue 1, Pages 1-10

PDF
collect

Progress in systemic therapy for triple-negative breast cancer

10.1007/s11684-020-0741-5

Cite this article

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a heterogeneous genetic profile. Chemotherapy exhibits substantial activity in a small subset of these patients. Drug resistance is inevitable. Major progress has been made in the genetic analysis of TNBC to identify novel targets and increase the precision of therapeutic intervention. Such progress has translated into major advances in treatment strategies, including modified chemotherapy approaches, immune checkpoint inhibitors, and targeted therapeutic drugs. All of these strategies have been evaluated in clinical trials. Nevertheless, patient selection remains a considerable challenge in clinical practice.

Keywords

triple-negative breast cancer ; immunotherapy ; targeted therapy

Previous article in issue

article in issue Next

Read

Download

Outline

Figures(5)

标签(1)

其他(2)

Frontiers of Medicine

Progress in systemic therapy for triple-negative breast cancer

Abstract

Keywords

评论

Outline

Figures(5)

标签(1)

其他(2)

Frontiers of Medicine

Progress in systemic therapy for triple-negative breast cancer

Abstract

Keywords

评论

Related Research